# Biotech Daily Digest ‚Äî 2026-01-31

**11 items from 3 sources**

## Summary by Source

- Eli Lilly Press Releases: 1 item
- Endpoints News: 9 items
- Fierce Biotech: 1 item


## Eli Lilly Press Releases

- **[Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility](https://investor.lilly.com/news-releases/news-release-details/lilly-selects-pennsylvania-home-its-newest-injectable-medicine)**  
  _Fri, 30 Jan 2026 11:00:00 -0500_  
  The $3.5 billion ¬† Lehigh Valley site will develop Lilly's next-generation weight-loss medicines, including retatrutide Company plans to create more than 2,800 manufacturing and construction jobs ¬† at Lilly's 10 th U.S.¬†manufacturing site announced since 2020 INDIANAPOLIS, Jan.


## Endpoints News

- **[Big Pharma earnings kick off; Third-round IRA drugs selected; Hengrui‚Äôs trailblazing moment; and more](https://endpoints.news/big-pharma-earnings-kick-off-third-round-ira-drugs-selected-hengruis-trailblazing-moment-and-more/)**  
  _Sat, 31 Jan 2026 11:00:35 +0000_  
  Welcome back to Endpoints Weekly! Fourth-quarter earnings season is in full swing, and our team covered reports this week from Teva, Roche, Sanofi, Takeda and Regeneron. CMS also unveiled the next 15 drugs subject to ...

- **[Bitterroot reverts to preclinical biotech in CD47 as CEO leaves](https://endpoints.news/bitterroot-reverts-to-preclinical-biotech-in-cd47-as-ceo-leaves/)**  
  _Fri, 30 Jan 2026 17:30:44 +0000_  
  Bitterroot Bio, a biotech from leading minds in the CD47 field, appears to have returned to the discovery stage after attempting to expand the potential of the "don't eat me" signal from the cancer field ...

- **[CHMP opposes Lilly‚Äôs Mounjaro in heart failure, backs Novo‚Äôs Kayshild](https://endpoints.news/chmp-opposes-lillys-mounjaro-in-heart-failure-backs-novos-kayshild/)**  
  _Fri, 30 Jan 2026 17:18:18 +0000_  
  EU regulators have refused to greenlight Eli Lilly‚Äôs weight loss drug Mounjaro as a treatment for a type of heart failure, while giving the go-ahead for Novo Nordisk‚Äôs semaglutide in liver disease.

 Lilly failed to ...

- **[Ultragenyx resubmits gene therapy for rare neuro disease to FDA](https://endpoints.news/ultragenyx-resubmits-gene-therapy-for-rare-neuro-disease-to-fda/)**  
  _Fri, 30 Jan 2026 16:50:40 +0000_  
  Ultragenyx has resubmitted its approval request for a rare disease gene therapy after the FDA rejected it last summer.

 UX111 is an AAV gene therapy designed to treat Sanfilippo syndrome type A. The company is ...

- **[Quince's steroid therapy for rare disease fails, shares tank](https://endpoints.news/quinces-steroid-therapy-for-rare-disease-fails-shares-tank/)**  
  _Fri, 30 Jan 2026 16:17:55 +0000_  
  Quince Therapeutics' once-monthly steroid-based treatment failed a Phase 3 trial for a rare genetic condition called ataxia-telangiectasia, prompting the Bay Area company to say it would stop development of the experimental ...

- **[Moderna licenses Phase 3 asset to Recordati; ProMIS' private placement](https://endpoints.news/moderna-licenses-phase-3-asset-to-recordati-promis-private-placement/)**  
  _Fri, 30 Jan 2026 16:05:18 +0000_  
  Plus, news about Lexicon Pharmaceuticals, Vaxcyte, ALX Oncology, BioMarin and 2048 Ventures:

 ü§ù Moderna signs rare disease drug deal with Recordati: The Italian drugmaker will pay Moderna $50 million upfront and ...

- **[Amgen ends partnership with Kyowa Kirin on immunology drug, despite Phase 3 wins](https://endpoints.news/amgen-ends-partnership-with-kyowa-kirin-on-immunology-drug-despite-phase-3-wins/)**  
  _Fri, 30 Jan 2026 16:04:43 +0000_  
  Amgen abruptly pulled out of a collaboration for a leading drug in its immunology pipeline on Friday, sending the asset back to its partner ahead of an FDA submission later this year.

 Amgen terminated its ...

- **[Lilly unveils $3.5B factory that will make retatrutide and other obesity drugs](https://endpoints.news/lilly-unveils-3-5b-factory-that-will-make-retatrutide-and-other-obesity-drugs/)**  
  _Fri, 30 Jan 2026 16:00:33 +0000_  
  Eli Lilly has budgeted $3.5 billion for a new weight loss injectable and device factory in Lehigh Valley, PA, which will manufacture its next-gen obesity drug retatrutide.

 The factory will also produce other weight loss ...

- **[Takeda is ‚Äònot in favor‚Äô of MFN, CEO-designate says](https://endpoints.news/takeda-is-not-in-favor-of-mfn-ceo-designate-says/)**  
  _Thu, 29 Jan 2026 18:01:01 +0000_  
  Takeda‚Äôs incoming CEO took a firm stance against President Donald Trump‚Äôs ‚Äúmost favored nation‚Äù deals with drugmakers on Thursday, while Sanofi and Roche shared new details about their negotiations with the White House.

 ‚ÄúIn general ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/moderna-cmo-steps-down-company-plucks-development-leader-immunocore" hreflang="en">Moderna's latest CMO steps down after barely a year</a>](https://www.fiercebiotech.com/biotech/moderna-cmo-steps-down-company-plucks-development-leader-immunocore)**  
  _Jan 30, 2026 10:19am_  
  Moderna Chief Medical Officer Jacqueline Miller, M.D., is stepping down after a little more than a year in the role. Meanwhile, the mRNA specialist is welcoming a new chief development officer in the form of David Berman, M.D., Ph.D.
